The video and presentation slides from our latest webinar, Contingency Management as a Tool for Alcohol Use Disorders among American Indian and Alaska Native People, with Dr. Michael McDonell are now available to view. The presentation from this event as well as our previous webinars can also be viewed here.
Join us on February 19th, 12 – 1pm PST for our next webinar in the NCARE Series.
Although American Indian and Alaska Native (AI/AN) communities have some of the highest alcohol abstinence prevalence rates compared to the general U.S. population, alcohol-related health inequities disproportionately impact AI/AN communities. Despite the need for evidence-based treatment options, little is known about effective alcohol treatments for AI/AN people. In this webinar we will discuss contingency management as a treatment for alcohol use disorders. Contingency management (CM) is an intervention in which tangible reinforcers (rewards) are provided when a patient demonstrates abstinence assessed by urine drug tests. Two projects evaluating CM as a tool for intervening in alcohol use disorders among AI/AN people are currently ongoing. The CM intervention has been implemented in alignment with existing cultural and community practices and with Elders and community leaders as champions of the intervention. The CM intervention provides rewards that are culturally tailored, specific and practical.
This webinar is free, but registration is required.
Rewarding Recovery Project
American Indians are disproportionately affected by alcohol and drug abuse. Contingency management (CM) is a treatment approach in which patients receive tangible rewards for abstaining from alcohol and drug abuse. Most previous evaluations have shown that the effect sizes of CM interventions are among the largest of all mental health and behavioral interventions. Our goal is to determine whether a culturally appropriate CM treatment program leads to reductions in alcohol and drug abuse on two American Indian reservations. Phases 1 and 2, which included focus groups with providers and patients, have been completed at both sites. Phase 3, which is a randomized controlled trial of CM for alcohol and drugs, is now in progress. As of June 2016, we have successfully consented 30 participants.